Breast feeding antidepressants
Breastfeeding & Psychiatric Medications - MGH Center for Women's Mental Health
Given the prevalence of psychiatric illness during the postpartum period, a significant number of women may require pharmacological treatment while nursing. Appropriate concern is raised, however, regarding the safety of psychotropic drug use in women who choose to breastfeed while taking these medications. While many women with postpartum illness delay treatment because they are worried that the medications they take may harm the nursing infant, the accumulated data indicates that the risk of adverse events in the nursing infant is low.
General Principles
Given the many benefits of breastfeeding, some women taking psychiatric medications may wish to nurse their infants. When making this decision, several variables must be considered. These include the known and unknown risks of medication exposure for the baby via breast milk, the effects of untreated illness in the mother, and the benefits of and maternal preferences for breastfeeding.
There are established health benefits of breastfeeding for babies and mothers.
Efforts have been made to quantify the amount of psychotropic medications and their metabolites in the breast milk of nursing mothers. In order to more accurately measure the infant’s exposure to medication, serum drug levels in the infant have also been assessed. From the available data, it appears that all medications, including antidepressants, antipsychotic agents, mood stabilizers, and benzodiazepines, are secreted into the breast milk. However, concentrations of these agents in breast milk vary considerably. The amount of medication to which an infant is exposed depends on several factors: factors pertaining to the specific medication, the maternal dosage of medication, the frequency of dosing and infant feedings, and the rate of maternal drug metabolism.
The decision to breastfeed while taking medications is more complicated when a baby is premature or has medical complications. The nursing infant’s chances of experiencing toxicity are dependent not only on the amount of medication ingested but also on how well any ingested medication is metabolized.
Most psychotropic medications are metabolized by the liver. During the first few weeks of a full-term infant’s life, there is a lower capacity for hepatic drug metabolism, which is about one-third to one-fifth of the adult capacity. Over the next few months, the capacity for hepatic metabolism increases significantly and, by about 2 to 3 months of age, it surpasses that of adults. In premature infants or in infants with signs of compromised hepatic metabolism (e.g., hyperbilirubinemia), breastfeeding typically is deferred because these infants are less able to metabolize drugs and may be more likely to experience adverse events.
Antidepressants in general are considered to be relatively safe for use during breastfeeding when clinically warranted, and SSRIs in particular are one of the best studied classes of medications during breastfeeding. Excellent and thorough reviews on the topic of antidepressants and breastfeeding have been published (Burt 2001; Weissman 2004).
In the most rigorous studies, nursing women have repeatedly provided breast milk samples and infant blood samples in order for investigators to quantify medication exposure to the infant.
Data have accumulated regarding the use of various antidepressant medications during breastfeeding. Available data on the use of tricyclic antidepressants (TCAs), fluoxetine, paroxetine, and sertraline during breastfeeding have been encouraging and suggest that the amounts of drug to which the nursing infant is exposed is low and that significant complications related to neonatal exposure to antidepressants in breast milk appear to be rare. Typically very low or non-detectable levels of drug have been detected in the infant serum, and one recent report indicates that exposure to medication in breast milk does not result in clinically significant blockade of serotonin (5-HT) reuptake in infants.
Although less information is available on other antidepressants, serious adverse events related to exposure to these medications have not been reported.
There have been a small number of case reports of adverse events in infants exposed to antidepressants in breast milk, including jitteriness, irritability, excessive crying, sleep disturbance, and feeding problems. In many cases it has not been possible to establish a causal link between these events and exposure to drug.
Many clinicians and their patients ask which antidepressant is the “safest” for breastfeeding. It is somewhat misleading to say that certain medications are “safer” than others. All medications taken by the mother are secreted into the breast milk, and there is no evidence to suggest that certain antidepressants pose significant risks to the nursing infant.
In terms of selecting an appropriate antidepressant, one should try to choose an antidepressant for which there are data to support its safety during breastfeeding (i.e., sertraline, paroxetine, fluoxetine, tricyclic antidepressants). However, some situations may warrant the use of antidepressants with less available safety data.
For example, if a woman has responded to a particular antidepressant in the past, it would be reasonable to consider using that antidepressant again. If she has been taking an antidepressant during the course of her pregnancy and has been doing well, it would be prudent to continue with that same antidepressant after delivery, as switching to another antidepressant may put her at increased risk for relapse.
We do not regularly measure drug levels in the breastfeeding mother or baby; however, there may be certain situations where information on exposure to drug in the child may help make decisions regarding treatment. If there is a significant change in the child’s behavior (e.g., irritability, sedation, feeding problems, or sleep disturbance), an infant serum drug level may be obtained. If levels are high, breastfeeding may be suspended. Similarly if the mother is taking a particularly high dosage of medication, it may be helpful to measure drug levels in the infant to determine the degree of exposure.
Anti-Anxiety Agents
Given the prevalence of anxiety symptoms during the postpartum period, anxiolytic agents are often used in this setting. Data regarding the use of benzodiazepines have been limited; however, the available data suggest that amounts of medication to which the nursing infant is exposed are low. Case reports of sedation, poor feeding, and respiratory distress in nursing infants have been published; however, the data, when pooled, suggest a relatively low incidence of adverse events in infants exposed to benzodiazepines in the breast milk.
Mood Stabilizers
For women with bipolar disorder, breastfeeding may pose more significant challenges. First, on-demand breastfeeding may significantly disrupt the mother’s sleep and thus may increase her vulnerability to relapse during the acute postpartum period. Second, there have been reports of toxicity in nursing infants related to exposure to various mood stabilizers, including lithium and carbamazepine, in breast milk.
Lithium is excreted at relatively high levels in the mother’s milk, and infant serum levels are about one-third to one-half of the mother’s serum levels. Reported signs of toxicity in nursing infants have included cyanosis, hypotonia, and hypothermia. Although breastfeeding typically is avoided in women taking lithium, some women may choose to use lithium while nursing. In this setting, the lowest possible effective dosage should be used and both maternal and infant serum lithium levels should be followed. In collaboration with the pediatrician, the child should be monitored closely for signs of lithium toxicity, and lithium levels, thyroid stimulating hormone (TSH), blood urea nitrogen (BUN), and creatinine should be monitored every 6-8 weeks while the child is nursing.
Several recent studies have suggested that lamotrigine reaches infants through breast milk in variable doses, with infant serum levels ranging from 20%-50% of the mother’s serum concentrations. In addition, maternal serum levels of lamotrigine increase significantly after delivery, which may contribute to the high levels found in nursing infants.
None of these studies have reported any adverse events in breastfeeding newborns. To read more on the safety of lamotrigine versus lithium, please reference this past blog.
One worry shared by clinicians and new mothers is the risk for Stevens-Johnson syndrome (SJS). This is a severe, potentially life-threatening rash, most commonly resulting from a hypersensitivity reaction to a medication, which occurs in about 0.1% of bipolar patients treated with lamotrigine. Thus far, there have been no reports of SJS in infants associated with exposure to lamotrigine. In fact, it appears that cases of drug-induced SJS are extremely rare in newborns. Despite the variable levels of medication found in infants in studies to date, none of these studies have reported any adverse events in the breastfeeding newborns. More research is required to assess the safety of lamotrigine in nursing infants, and decisions regarding the use of this drug in breastfeeding women involves a careful consideration of the risks and benefits of using this medication.
Although the American Academy of Pediatrics has deemed both carbamazepine (Tegretol) and valproic acid (Depakote) to be appropriate for use in breastfeeding mothers, few studies have assessed the impact of these agents on infant well-being. Both of these mood stabilizers have been associated in adults with abnormalities in liver function and fatal hepatotoxicity. Hepatic dysfunction secondary to carbamazepine exposure in breast milk has been reported several times. Most concerning is that the risk for hepatotoxicity appears to be greatest in children younger than 2 years of age; thus, nursing infants exposed to these agents may be particularly vulnerable to serious adverse events. In those women who choose to use valproic acid or carbamazepine while nursing, routine monitoring of drug levels and liver function tests in the infant is recommended. In this setting, ongoing collaboration with the child’s pediatrician is crucial.
Antipsychotic Agents
Information regarding the use of antipsychotic drugs is limited and is particularly lacking for the newer atypical agents.
While the use of chlorpromazine has been associated with adverse events including sedation and developmental delay, adverse events appear to be rare when medium- or high-potency agents are used.
Less data, however, is available on the atypical antipsychotic agents. Data on clozapine suggest that it may be concentrated in the breast milk; however, there are no data on infant serum levels, making it difficult to interpret the relevance of this finding. Given the severity of adverse events associated with clozapine exposure in adults (i.e., decreased white blood cell count), the use of this medication should be reserved for those with treatment-refractory illness, and monitoring of white blood cell counts in the nursing infant is mandatory.
There is very limited data on the use of other atypical antipsychotic agents during lactation; however, limited data available on olanzapine, risperidone, and quetiapine suggest that the excretion of these medications in breast milk is low and that adverse effects appear to be rare.
Monitoring of the infant is encouraged, as there has been one report of an infant who had sedation on a higher dose of olanzapine, which resolved after the mother’s dose was halved to 5mg/day. To date, there have been no reports on the use of the antipsychotic medications, ziprasidone (Geodon) and aripiprazole (Abilify) while breastfeeding.
Treatment Guidelines
Consultations regarding the safety of psychiatric medications in breastfeeding women should include a discussion of the known benefits of breastfeeding to mother and infant and the possibility that exposure to medications in the breast milk may occur. Although routine assay of infant serum drug levels was recommended in earlier treatment guidelines, this procedure is probably not warranted; in most instances low or non-detectable infant serum drug levels will be evident and serious adverse side effects are rarely reported. This testing is indicated, however, if neonatal toxicity related to drug exposure is suspected.
Infant serum monitoring is also indicated when the mother is nursing while taking lithium, valproic acid, carbamazepine, or clozapine.
We have varying amounts of study pertaining to individual medications, with SSRIs being among the best studied medications in breastfeeding. Also, data that is available informs most specifically on the short-term safety of these medications, and long term systematic data are unavailable. Therefore, in each individual case, the known and unknown risks of exposure must be balanced with the risks of untreated maternal illness in the mother and her desire to breastfeed.
For the latest information on breastfeeding and psychiatric medication, please visit our blog.
How do I get an appointment?
Despite the high rate of postpartum depression seen in women after childbirth, the illness is frequently not treated because of women’s wish to breastfeed. Clinical consultation is offered to women who may benefit from use of medication while breastfeeding, taking into account all available information regarding the safety of this practice during lactation.
Consultations regarding treatment options can be scheduled by calling our intake coordinator at 617-724-7792.
At this time the Center does not have any active studies investigating breastfeeding and psychiatric medications. New studies may become active in the near future. In order to remain informed about any studies for which you may be eligible, click here
Antidepressant Use in the Breastfeeding Patient
US Pharm. 2021;46(5):17-22.
ABSTRACT: It is well known that the peripartum period carries an increased risk of psychiatric disorders in the mother, and treatment is often necessary; however, given concerns about medication exposure in infants, uncertainty exists on how to safely manage treatment in breastfeeding patients with psychiatric illnesses. Additionally, the impact of the drug on milk production should be considered. However, pharmacologic treatment is not always incompatible with breastfeeding. As patients and providers may seek information on the use of antidepressants and other psychotropics while breastfeeding, pharmacists must consult current resources to keep abreast of risks, benefits, and treatment guidelines.
By optimizing care for breastfeeding patients, pharmacists can help prevent adverse outcomes in both mother and baby.
It is well known that the first few months postpartum carry an increased risk of onset or worsening of mental illness in the mother. Mental-health conditions that may be experienced during this period include depressive and anxiety disorders, posttraumatic stress disorder, obsessive compulsive disorder, eating disorders, and (more rarely) psychotic disorders.1 Major risk factors for the development of depressive and anxiety disorders in the peripartum period include a history of psychiatric illness, an insufficient support network, and prior adverse life events. Additionally, during the postpartum period, several other elements may contribute to the onset or worsening of mental disorders, including reduced quality and quantity of sleep, postpartum hormonal fluctuations, and genetic factors.1 Many women choose to breastfeed, resulting in the necessity to address the safety of psychotropics use with regard to infant exposure.
This article will chiefly discuss the use of antidepressants in breastfeeding women.
It is recommended that breastfeeding women with milder psychiatric symptoms engage in lower-risk treatment such as psychological interventions; however, those with more severe symptoms may require pharmacologic treatment.1 As with any clinical decision, the risks and benefits of continuing or initiating a medication should be carefully weighed against the risks and benefits of discontinuing or avoiding medications during breastfeeding.
Although breastfeeding is generally recommended for its benefits to the baby, many women experience challenges with latching, milk supply, and sleep disruption, so these factors should be assessed in order to limit resultant distress.1,2 If sleep disruption caused by late-night breastfeeding sessions is having a significant negative impact on psychiatric symptoms, a discussion could be initiated about switching to formula feeding at night or pumping breast milk so that the partner or spouse can handle nighttime feedings.
1 A patient already taking an antidepressant may either choose to continue it and switch to formula feeding if adverse effects (AEs) on the newborn become a concern or opt to forego the medication and try nonpharmacologic treatments, such as psychotherapy. It is important to recognize, however, that pharmacologic treatment is not always incompatible with breastfeeding.
The risks of remaining on medications while breastfeeding vary, but the main risks related to switching or discontinuing pharmacologic treatment during this period involve suboptimal outcomes including relapse, uncontrolled psychiatric symptoms, and adverse outcomes such as death from suicide.3 The patient’s mental-illness history, including symptom severity, history of suicidality, and history of impaired quality of life due to symptoms, should be considered. It should be kept in mind that untreated maternal mental illness can also affect the infant if it impairs the mother’s ability to take care of the child properly or—in more severe cases—results in direct harm to the child.
Additionally, the potential impact of the drug on milk production should be considered.
Finally, the infant’s age must be taken into account. Hepatic functionality is still developing at age 3 to 6 months, so babies of this age may be unable to efficiently metabolize any medications they are exposed to via breast milk, which may result in elevated plasma concentrations beyond what is anticipated. This decreased ability to metabolize drugs may be even more pronounced in preterm infants.4 Another consideration is whether the infant is taking any medications, as there may be interactions between the infant’s medications and the mother’s. Finally, the amount of milk the infant is consuming may also impact treatment decisions because, compared with partially breastfed infants, an exclusively breastfed infant is at higher risk for medication exposure. These factors must be considered on a case-by-case basis, with the healthcare team and the patient engaging in shared decision making.
Breastfed infants of mothers who continue a medication from pregnancy into the postpartum period may be less likely to experience neonatal adaptation compared with formula-fed infants.5 Treatment goals for postpartum psychiatric disorders are to reduce the psychiatric symptoms and support the relationship between mother, child, and family unit.1
To estimate an infant’s potential exposure to medication during breastfeeding, the milk-to-plasma (M/P) concentration ratio is often used. The most common cutoff point for concern over drug accumulation in breast milk is when the M/P ratio exceeds 1.6 Another way to measure exposure is the relative infant dose (RID) or percent maternal dose, which is calculated by dividing the mg/kg/day ingested via breast milk by the mg/kg/day maternal dose. It is generally accepted that an RID of 10% or more of the maternal dose is clinically significant and potentially concerning.7-9
Drug Passage Into Breast MilkMultiple factors can affect a medication’s ability to pass into breast milk.
9,10 For example, in the first 3 days postpartum, spaces between the mammary epithelial cells allow larger molecules to penetrate the milk. The amount of drug that the newborn may be exposed to during this time is limited owing to the small volume consumed.9,10 Following this phase, milk production increases, and the spaces between the mammary epithelial cells close over a 1- to 2-week period. Subsequently, medications are able to penetrate breast milk primarily by passive diffusion across the mammary epithelium, which acts as a semipermeable lipid barrier. An exception occurs in the event of maternal infections such as mastitis, wherein the passage of drug molecules may generally increase and larger molecules again may be able to pass through.10
The rate of passage from maternal plasma into breast milk is determined both by medication lipid solubility and by molecular weight, with smaller-molecular-weight molecules having increased passage. Psychotropic drugs are generally lipophilic, which permits them to dissolve in the mammary epithelial cell membrane and pass more easily into breast milk.
It also allows the drug to concentrate in the milk fat, which ranges from 10% in hindmilk to 2% to 3% in foremilk.9,10
Medications that enter the milk compartment quickly will achieve a greater initial concentration, resulting in a higher M/P ratio. Those that enter the milk compartment slowly may not achieve concentrations as high as those in the maternal plasma, as the compartment is emptied at each nursing session, thus requiring new transport of the drug.9,10
Protein-binding also has an impact on medication passage into breast milk, as highly protein-bound drugs are less able to penetrate the milk compartment.9,10 Additionally, the drug’s pH has an effect on passage into breast milk. According to the pH partition theory, ionized forms of weak bases concentrate in the milk, whereas weak acids are trapped in the plasma.9 To summarize, the ideal medication for passing into breast milk is nonionized and has a lower molecular weight, high lipophilicity, low protein-binding, and high pKa.
(pKa, the negative log of the acid dissociation constant Ka, expresses the acidity of a weak acid, whereas a lower pKa denotes a stronger acid.9,10)
All antidepressants pass into the breast milk to some degree.2 Therefore, clinical-treatment guidelines for depression in postpartum breastfeeding mothers often recommend psychotherapy first-line, with second-line therapy including agents such as citalopram, escitalopram, and sertraline.2,11 Other options may be considered in patients who have responded well to other agents in the past. In a pooled analysis of antidepressant concentrations in lactating mothers, breast milk, and nursing infants, infants who were exposed to nortriptyline, paroxetine, or sertraline were least likely to have detectable or elevated serum drug concentrations (>10% of maternal level).8 In the same analysis, citalopram or fluoxetine use in a nursing mother often resulted in elevated serum drug concentrations in the infant.
8
Although citalopram use sometimes leads to elevated serum drug concentrations in the infant that are beyond the 10% threshold, the reported AEs for infants are relatively mild and include drowsiness, weight loss, restlessness, irritability, and uneasy sleep.5 Neonatal adaptation syndrome and withdrawal effects from citalopram have also been reported, including irregular breathing, apnea, disordered sleep, and hypotonia.12
Case reports have identified potential AEs associated with fluoxetine during breastfeeding, including fussiness, drowsiness, and impaired infant weight gain.5 For this reason and because of the higher concentrations in infant serum, it is often recommended that an antidepressant with less excretion into the milk compartment be used when feasible.
Although escitalopram passes into breast milk only in low concentrations, there have been a few cases of AEs, including irritability, in nursing infants.5 There has been a single case report of necrotizing enterocolitis in an infant exposed to escitalopram via breast milk, but causality was not determined.
13 Additionally, in one report, seizure activity occurred in an infant exposed to both escitalopram and bupropion via breast milk, but this was thought to be related to the bupropion exposure.14
Because sertraline passes into breast milk in low concentrations, it is considered a preferred agent for breastfeeding women.2,10 AEs in breastfed infants exposed to sertraline are rare, but diarrhea, drowsiness, restlessness, insomnia, and poor neonatal adaptation have been noted.5 In one case report, an infant exposed to sertraline via breast milk who was later determined to have genetic polymorphisms of the CYP450 enzymes involved in sertraline metabolism experienced hyperthermia, alterations in muscle tone, and high-pitched crying related to elevated sertraline concentrations.15 This case illustrates that medications can affect all infants slightly differently owing to individual characteristics.
Paroxetine is not recommended in pregnancy based on the risk of cardiovascular malformations if used in the first trimester; however, because it has been shown to pass into breast milk only in low concentrations, it may be more acceptable for use during lactation.
8 AEs in nursing infants exposed to paroxetine through breast milk are rare and generally mild; restlessness, constipation, insomnia, poor neonatal adaptation, alertness, agitation, and poor feeding have been reported.5
Venlafaxine and its active metabolite have been shown to pass into breast milk in higher concentrations (M/P ratio >1).16 The literature notes several cases of suspected withdrawal in breastfeeding newborns whose mothers were taking venlafaxine during pregnancy and postpartum.5
Not much literature is available on nursing mothers taking mirtazapine, but there is one report of infant restlessness in a breastfeeding mother who was taking both mirtazapine and paroxetine.5,17 Similarly, few studies exist on bupropion use in breastfeeding women; however, two cases of seizures in infants exposed to bupropion via breast milk have been reported.14,18 There are no published reports on mother and nursing infant pairs for newer antidepressants such as vortioxetine and vilazodone, so little is known about their effects; therefore, it may be best for patients who are planning to breastfeed to opt for an alternative agent.
5
One important factor to consider regarding medication use during breastfeeding is the agent’s impact on milk production. It has been observed that increases in serotonin levels cause early involution of mammary glands, thereby reducing milk production, which has led to theoretical concerns about milk supply in nursing mothers taking antidepressants with serotonergic properties.19 Additionally, postmarketing reports of selective serotonin reuptake inhibitors have identified proposed “dopamine-dependent” AEs that may affect milk production, such as galactorrhea, mammary-gland hypertrophy, and hyperprolactinemia.20 However, in a retrospective cohort study that used the galactogogue domperidone as a marker of low milk supply, no association was found between late-pregnancy serotonin reuptake inhibitor (SRI) use and domperidone use, indicating that SRIs do not adversely affect milk supply.19
Resources for Drugs in LactationSeveral rating scales exist for determining risks of medications used in lactation.
The most widely used resources include Briggs and colleagues’ Drugs in Pregnancy and Lactation, which rates drugs according to seven risk categories, and Hale’s Medications and Mothers’ Milk, which uses five lactation-risk categories.9,21,22 Categories range from “contraindicated in breastfeeding” to “compatible/safest,” which is reserved for agents that have been studied in breastfeeding humans and have not demonstrated any AEs in infants.9,21 Uguz recently proposed a third scoring system specifically for psychotropic medications that rates each agent on a 10-point scale incorporating data on six items: reported total sample, reported maximum RID, reported sample size for RID, infant plasma drug concentrations, prevalence of observed AEs, and reported serious AEs.22
Although these categorical ratings are important to keep in mind and may be a good starting point for researching the effects of medications during breastfeeding, more in-depth resources should be consulted in order to fully inform clinical decisions.
Other resources include the drug’s package insert (PI), the LactMed online database, MotherToBaby, and the InfantRisk Center.5,23,24 Each PI contains a lactation section organized into three distinct topics: risk summary, clinical considerations, and data. LactMed, which is maintained by the National Library of Medicine, includes information on medication concentrations in breast milk as well as summaries of AEs noted in the literature and any effects on milk production.5 MotherToBaby is a telephone- and Web-based service of the Organization of Teratology Information Specialists that is available to both patients and healthcare providers.23 The InfantRisk Center, a global call center located at the Texas Tech University Health Sciences Center School of Medicine, helps providers and patients evaluate the risk of multiple drug exposure to the infant.24
During the postpartum period, mothers may be seeking information regarding the compatibility of their medications with lactation.
Likewise, patients’ healthcare providers may seek input from the pharmacist on this issue. Although many resources are available, much remains unknown about the passage of specific drugs into breast milk and about related AEs. In determining the safety of any medication in a breastfeeding woman, it is important for the pharmacist to keep in mind that there are essentially two patients: the mother and the infant. Information gathered should include not only the mother’s health conditions and current medications, including indications, dosing, and anticipated duration of therapy, but also the infant’s age, weight, preterm/term status, current health conditions, current medications, and percentage of breast milk in the diet.22 The use of evidence-based resources will help the pharmacist evaluate and share the most up-to-date information regarding medication use in breastfeeding. Breastfeeding women who are thinking about discontinuing maintenance antidepressant therapy should be encouraged to discuss their concerns with the prescriber in order to avoid any risk of relapse, withdrawal, or other unintended harmful effects.
1. Meltzer-Brody S, Howard LM, Bergink V, et al. Postpartum psychiatric disorders. Nat Rev Dis Primers. 2018;4:18022.
2. Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. Breastfeed Med. 2015;10(6):290-299.
3. Johannsen BM, Larsen JT, Laursen TM, et al. All-cause mortality in women with severe postpartum psychiatric disorders. Am J Psychiatry. 2016;173(6):635-642.
4. Berle JØ, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7(1):28-34.
5. Drugs and lactation database (LactMed) [Internet]. Bethesda, MD: National Library of Medicine; 2021. www.ncbi.nlm.nih.gov/books/NBK501922/. Accessed April 2, 2021.
6. Ito S. Mother and child: medication use in pregnancy and lactation. Clin Pharmacol Ther. 2016;100(1):8-11.
7. Sachs HC, Committee on Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics.
Pediatrics. 2013;132(3):e796-e809.
8. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078.
9. Berens PD, Hale TW. Principles of drug therapy in pregnancy and lactation. In: O’Connell MB, Smith JA, eds. Women’s Health Across the Lifespan: A Pharmacotherapeutic Approach. 2nd ed. New York, NY: McGraw-Hill Medical; 2019.
10. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52.
11. MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588-603.
12. Franssen EJF, Meijs V, Ettaher F, et al. Citalopram serum and milk levels in mother and infant during lactation.
Ther Drug Monit. 2006;28(1):2-4.
13. Potts AL, Young KL, Carter BS, Shenal JP. Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. J Perinatol. 2007;27(2):120-122.
14. Neuman G, Colantonio D, Delaney S, et al. Bupropion and escitalopram during lactation. Ann Pharmacother. 2014;48(7):928-931.
15. Müller MJ, Preuss C, Paul T, et al. Serotonergic overstimulation in a preterm infant after sertraline intake via breastmilk. Breastfeed Med. 2013;8(3):327-329.
16. Schoretsanitis G, Augustin M, Sassmannshausen H, et al. Antidepressants in breastmilk; comparative analysis of excretion ratios. Arch Womens Ment Health. 2019;22(3):383-390.
17. Uguz F. Short-term safety of paroxetine plus low-dose mirtazapine during lactation. Breastfeed Med. 2019;14(2):131-132.
18. Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of a possible infant seizure.
J Clin Psychiatry. 2004;65(6):881-882.
19. Grzeskowiak LE, Leggett C, Costi L, et al. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. Br J Clin Pharmacol. 2018;84(6):1373-1379.
20. Damsa C, Bumb A, Bianchi-Demicheli F, et al. “Dopamine-dependent” side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry. 2004;65(8):1064-1068.
21. Instructions for use of the reference guide. In: Briggs GC, Freeman RK, Towers CV, Forinash AB, eds. Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
22. Uguz F. A new safety scoring system for the use of psychotropic drugs during lactation. Am J Ther. 2021;28(1):e118-e126.
23. MotherToBaby. Is it safe for me and my baby? https://mothertobaby.org/. Accessed February 28, 2021.
24. InfantRisk Center.
About the InfantRisk Center. www.infantrisk.com/about-infantrisk-center. Accessed February 28, 2021.
The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.
To comment on this article, contact [email protected].
Can I take antidepressants while breastfeeding? - Empathy
At the beginning of August, WHO initiated the Breastfeeding Support Week around the world, the purpose of which is to remind women about the benefits of natural breastfeeding. We will touch upon such an urgent issue as the treatment of depression in nursing mothers.
Is it safe to take antidepressants while breastfeeding? Should breastfeeding mothers stop taking drugs? The Deputy Chief Physician of the Empathy Center, Candidate of Medical Sciences, psychiatrist Irina Valerievna Gorshkova answers:
“The desire to continue breastfeeding is often the main reason women refuse to see a psychiatrist.
This is not at all surprising, because the instructions for prescribed drugs may indicate that there is no data on their safety for nursing mothers, or it is written that the drug passes into breast milk. In this regard, there is often an opinion that taking antidepressants by a young mother is not safe for a child. However, this statement can be disputed.
For more than 10 years, studies have been conducted and published that prove the safety of using antidepressants during breastfeeding (mainly SSRIs). There are also many studies confirming the need to treat depression in a woman in the postpartum period, which directly affects the health of not only the mother, but also the baby. In simple terms, sometimes prescribing antidepressants while breastfeeding is a much smarter and safer decision than leaving a woman in a depressed state.
Breastfeeding is very important for the full development of the child, moreover, its beneficial effect on the health of both the baby and the mother has long been known.
Therefore, unjustified cancellation of breastfeeding due to fear of antidepressants can negatively affect both the condition of the child and the psycho-emotional state of the woman, cause her to feel guilty and inferior.
Prescribing antidepressants during breastfeeding is not only possible but necessary , provided that the doctor correlates the expected benefits and possible risks of taking the drug. And let's not forget that the treatment of depression involves not only medication, but also psychotherapy. With a mild degree of severity of a depressive episode, preference is given precisely to psychotherapeutic methods. Medication support is most often prescribed in combination with psychotherapy.”
How can we help?
| If you have found some of the described symptoms in yourself or your loved ones, this may indicate the development of a mental disorder. In this case, it is worth contacting a psychiatrist for diagnosis and initiation of timely treatment. |
In addition to face-to-face communication , we offer remote consultation service (online reception) , which is not inferior to a face-to-face meeting in terms of quality. Thus, you can get qualified help from a high-level specialist , no matter where you are located. In our center for mental health and psychological assistance, within walking distance from the Elektrozavodskaya metro station (Moscow) and the Novokosino metro station (Reutov), specialists who have extensive experience in treating mental disorders work. We use the most modern and advanced techniques, guided by the principles of evidence-based medicine. Effective assistance and confidentiality of information constituting a medical secret are guaranteed.
Antidepressants while breastfeeding. Translation of studies
When a woman with postpartum depression finally reaches the doctor, she is often faced with a painful choice:
⠀
“Wean the baby or come later - while you are on breastfeeding, we cannot treat you in any way!”
⠀
But according to evidence-based medicine, this is not at all the case!
⠀
Maria Anikeeva translated for you several articles from the internationally recognized scientific portal PubMed on the use of antidepressants during breastfeeding.
Treatment with antidepressants for breastfeeding breastfeeding
Original: ncbi.nlm.nih.gov/pmc/articles/PMC2 6/
Authors: Teresa Lanza di Scalea, M.D. and Katherine L. Wisner, M.D. “Clin Obstet Gynecol.”
Abstract:
We reviewed English-language studies published in MEDLINE, PreMEDLINE, Current Contents, Biological Abstracts, and PsycINFO from June 2002 to December 2008 and obtained reports on serum concentrations of antidepressants mother, breast milk and neonatal serum, as well as short-term and long-term clinical consequences for newborns.
During the review, we reviewed 31 scientific publications.
Breastfeeding and antidepressant treatment are not mutually exclusive.
From the point of view of evidence-based medicine, the safest for breastfeeding treatments are sertraline, paroxetine, nortriptyline and imipramine.
PRACTICE GUIDELINES
To date, three scientific panels have developed practice guidelines for the use of antidepressants while breastfeeding.
These are as follows:
1) The choice of a specific treatment for a breastfeeding mother should be based on an individual analysis of the risk-benefit ratio, the consequences of an untreated disease in the mother, the risk and benefit of a particular treatment, the risk and benefit of breastfeeding for a given couple mother and newborn.
2) The patient has the right to make an informed decision based on full information regarding the availability and risk/benefit ratio of a particular treatment.
3) Mild to moderate postpartum depression is primarily treated with non-pharmacological treatment, such as psychotherapy.
4) For moderate to severe depression, or if the woman does not respond to (or refuses) psychotherapy, antidepressants or a combination of antidepressants and non-drug treatments should be considered.
5) The specific antidepressant is selected based on clinical factors, in particular treatment that has been effective for the woman in previous episodes of depression.
6) If a woman is experiencing depression for the first time, sertraline or paroxetine should be the first choice.
7) The antidepressant should be given at the lowest effective dose and then gradually increased.
8) Monotherapy is preferred.
9) The clinical condition of the mother and the newborn should be monitored, especially if the child has a disease or was born with a low birth weight.
10) Routine monitoring of neonatal serum levels is not recommended unless clinically indicated or necessary for research purposes.
Use of antidepressants for breastfeeding breastfeeding
Original: ncbi.nlm.nih.gov/pmc/articles/PMC3267169/
Authors: Jan Øystein Berle1,* and Olav Spigset “Curr Womens Health” Rev. February 2011; 7(1).
Summary:
Infant exposure to antidepressants through breast milk is generally low to very low.
We believe that when antidepressant treatment is indicated women with postpartum depression, there is no need to stop breastfeeding feeding.
The first choice should be paroxetine and sertraline.
Despite some concerns about the use fluoxetine, citalopram and venlafaxine, we nevertheless believe that if mother took one of these drugs during pregnancy, she may continue to breastfeed during treatment with these drugs and in the postpartum period.
However, the individual ratio must always be calculated risk and benefit.
PRACTICAL RECOMMENDATIONS
Several attempts have been made to guide clinical decision making regarding breastfeeding during antidepressant treatment, including some of the most comprehensive reports and reviews.
In addition, practice guidelines have been developed by scientific organizations, but two of these documents focus more on medication during pregnancy rather than the postpartum period and therefore do not provide clear guidance on specific drug selection for breastfeeding women.
According to most of these guidelines, the choice of specific treatment for a breastfeeding mother should be based on an individual risk-benefit analysis.
Such an analysis should take into account: the consequences of untreated diseases for the mother and newborn, the risk and benefit of a particular treatment for the mother and newborn, the risks and benefits of breastfeeding or cessation of breastfeeding for the newborn, possible risks for mothers associated with the termination of breastfeeding, as well as the desire of the mother breastfeed.
There is a risk of drug exposure to the newborn, but there is also a risk associated with untreated depression or failure of newborns to receive mother's milk.
In this regard, whatever clinical decision is made in the context of postpartum depression, it will in any case be associated with one or another risk.
Mild to moderate postpartum depression is primarily treated with non-pharmacological treatment, such as psychotherapy.
For women with moderate to severe depression and also in some other cases such as anxiety disorder, medical treatment is usually more justified.
In addition, antidepressants are also preferred for the prevention of new episodes/relapse in women with a history of postpartum depression or who took antidepressants during pregnancy.
When it comes to choosing a specific antidepressant, sertraline or paroxetine is generally preferred over other SSRIs due to the low exposure of these drugs to neonates.
However, treatment of women of reproductive age paroxetine in general has a number of disadvantages.
- First, if a woman requires long-term treatment, on the background of which she then becomes pregnant again, paroxetine is not recommended as a drug of first choice due to the risk of fetal heart defects.
- Second , compared with other SSRIs, paroxetine has a higher risk of withdrawal if a woman misses one or more doses (women who are overwhelmed, sleep-deprived after childbirth are more likely to experience this than other patients).
Most recommendations are to avoid fluoxetine and citalopram whenever possible, or use them with great caution due to their higher neonatal plasma concentrations than other drugs and the risk of adverse effects on the newborn .
However, if the mother was previously treated with fluoxetine or citalopram and the treatment was effective, or if the mother took one of these drugs during pregnancy, this drug can be used in the postpartum period.
As a result of our group's study, including a review of various SSRIs and venlafaxine, we concluded that when antidepressant treatment is indicated for women with postpartum depression, there is generally no need to stop breastfeeding.
The number of newborns exposed to antidepressants varies considerably depending on the drug: for fluoxetine, paroxetine, sertraline and citalopram it is about 100 cases, for other more modern antidepressants it is less than 25.
Some degree of uncertainty inevitably remains in for products with few observed effects on newborns, as well as when there were no cases of negative impact.
Therefore, drugs for which little data has been collected, such as fluvoxamine, venlafaxine, duloxetine, reboxetine, bupropion, and mirtazapine, should not be used as first choice therapy. However, they can be prescribed in special cases.
Some reviews and guidelines recommend that the newborn be monitored, especially if the newborn has a medical condition, was born prematurely, or was born with a low birth weight.
However, given the very low risk of drug exposure to the newborn and the non-specific nature of the possible symptoms in the child, we believe that in general there is no need for any regular or specific follow-up examinations.
As a general rule, it is also not recommended to routinely check the concentration of the drug in breast milk and / or blood serum of the newborn.
However, this test may be useful if the child develops symptoms that indicate possible drug exposure.
In addition, in our experience, often when a mother who really wants to continue breastfeeding, sees that, according to the analyzes the concentration of the drug in the milk and / or blood plasma of the child is negligible, this she is very calming.
Thus, there are arguments in favor of tracking the concentration of the drug in the milk or blood plasma of the newborn more freely, than is often recommended, at least when conducting such analysis is not difficult.
Since antidepressants are lipophilic drugs, their excretion into breast milk is potentially dependent on the content of triglycerides in milk.
However, the nutritional value of human milk is also related to its triglyceride content.
Therefore, there is no point in trying to avoid a sufficiently small additional exposure of the drug to the child through breast milk with high or low triglycerides.
Most antidepressants have a long duration half-life, and their concentration in breast milk in the interval between doses in general changes little.
Therefore avoiding breastfeeding during peak plasma concentrations, for example by taking the daily dose in the evening and avoiding breastfeeding at night, will only marginally reduce the dose that the newborn will receive through breast milk.
Trying to express and discard breastmilk to reduce the baby's drug exposure is also of little value.
- First , there are no indicators by which it would be possible to determine that a certain threshold for the risk of drug exposure to a child is reduced, for example, by 30-50%.
- Secondly , if breast milk is poured out, then this indirectly implies that the negative effect of the drug is possible only if the child is exclusively breastfed.
- Thirdly , in our experience, after a relatively short time, cases of, for example, 50% breastfeeding and 50% artificial feeding often end up exclusively with artificial feeding.
Breastfeeding and psychotropic medications
Massachusetts Clinical Hospital for Women's Mental Health Publication
💢 General Principles
Knowing the many benefits of breastfeeding, some women on psychiatric drugs want to continue breastfeed your children.
When making the appropriate decision, several variables, including: known and unknown risks of drug exposure on a child through breast milk, the consequences of an untreated disease in the mother, the benefits of breastfeeding; and the mother's desire to breastfeed.
Breastfeeding has been scientifically proven to have beneficial effects on maternal and newborn health.
Attempts have been made to measure the concentration of psychotropic drugs and their metabolites in the breast milk of lactating women.
In order to accurately measure the level of exposure of a drug to a child, an analysis of its concentration in the blood serum of newborns was also carried out.
According to available data, it seems that all medications, including antidepressants, antipsychotics, stabilizers mood and benzodiazepines pass into breast milk.
However, the concentration of these drugs in breast milk varies considerably.
Concentration of drug exposed to child, depends on several factors: the properties of a particular medication, prescribed mother of the dosage of the drug, the frequency of taking the drug and feeding, and also the rate of drug metabolism in the mother's body.
Breastfeeding decision algorithm for the background of taking medication becomes more complicated if the baby is premature or suffers complications.
The risk that the infant will experience toxic effects, depends not only on the concentration of the drug that has entered his body, but also from drug metabolism.
Most psychotropic drugs are metabolized in liver.
In the first few weeks of life, hepatic clearance in term infants children is reduced and is approximately 1/3 - 1/5 of the clearance of similar drugs in adults.
Over the next few months, hepatic clearance in the child increases significantly and, by the age of about two to three months, exceeds clearance in adults.
Breastfeeding premature babies or babies with symptoms any disorder of hepatic metabolism (eg, hyperbilirubinemia) most often you have to suspend, because.
These children have low metabolism. drugs, and therefore the risk of adverse effects is higher.
💢 Antidepressants
In general, antidepressants are considered relatively safe to use during breastfeeding when clinically warranted , and SSRIs in particular are one of the best studied classes of drugs used during breastfeeding.
Excellent detailed studies have been published on use of antidepressants during breastfeeding (Burt 2001; Weissman 2004).
With the most rigorous research in order to determine the level of exposure of the drug to the infant, analyzed repeatedly mother's breast milk and newborn blood.
Collected data on the use of various antidepressants while breastfeeding.
Data available on the use of tricyclic antidepressants, fluoxetine, paroxetine and sertraline during breastfeeding feeding are very encouraging and suggest that the concentration the drug to which the newborn is exposed is small, and that significant complications associated with the effect of a particular drug on newborn, apparently occur rarely.
A very low or undetectable concentration of the drug is usually detected in the blood serum of a newborn.
And one of the recent reports reported that in infants, fed by mothers who take these drugs, there are no clinically significant inhibition of serotonin (5-HT) reuptake.
Although there are fewer data on other antidepressants, there are no serious adverse effects from the effects of these drugs on newborns were not reported.
There have been a small number of cases in which infants exposed to antidepressants through breast milk have been observed adverse effects, including irritability, irritability, excessive crying, sleep disturbance and lack of appetite.
In many cases it was not possible to install causal relationship between these manifestations and drug exposure.
Many practitioners and patients wonder what antidepressant is safest when breastfeeding.
In fact, the claim that certain drugs "safer" than others can be misleading.
All drugs taken by the mother pass into breast milk, but there is no evidence to suggest that certain antidepressants pose a significant risk to the nursing infant.
When choosing an antidepressant, you should choose a drug that for which there is sufficient data on the safety of breastfeeding (ie, sertraline, paroxetine, fluoxetine, tricyclic antidepressants).
However, in some situations it may be justified the use of antidepressants, the safety of which is less known.
For example, if a woman has responded well to a certain antidepressant in the past, it is wise to use it again.
If she took an antidepressant during pregnancy and feels well, it is advisable to use the same antidepressant after delivery as well. switching to another drug may increase the risk of relapse.
Regularly monitor the concentration of the drug in the blood of a nursing mother or child is not needed.
However, in certain cases when making a decision relative further treatment may need information on the level the effect of the drug on the child.
If there are significant changes in the child's behavior (for example, irritability, lethargy, lack of appetite or sleep disturbance), the concentration of the drug in the blood serum of the newborn can be checked.
If the concentration is high, breastfeeding can be suspended for a while (here is a detailed description of how to organize temporary weaning as safely as possible for both mother and baby).
Similarly, if the mother takes the drug very high dosage, it will not be superfluous to check the concentration of the drug in the serum the baby's blood to check the level of exposure to the newborn.
💢 Anti-anxiety agents
Due to the high prevalence of anxiety disorders in the postpartum period, anti-anxiety medications are often prescribed to breastfeeding women.
Only limited data available for use in breastfeeding benzodiazepines; however, available data allow suggest that in such cases the newborn is exposed to a small drug concentration.
Clinical reports of lethargy, loss of appetite and respiratory depression in infants.
However, summarizing the data shows a comparatively low incidence of adverse effects in newborns, exposed to benzodiazepines through breast milk.
💢 Mood stabilizers
For women with bipolar disorder breastfeeding may be associated with more serious problems.
- First, , feeding on demand can significantly disrupt a mother's sleep and thus increase her vulnerability to relapse in the early postpartum period.
- Second, , neonatal toxic effects of various mood stabilizers, including lithium and carbamazepine, have been reported through breast milk.
Lithium passes into mother's milk in relatively high concentrations , and in the blood serum of the newborn its concentration is from 1/3 to 1/2 of its concentration in the mother's blood serum.
According to published data, signs of toxic effects include cyanosis, hypotension, and hypothermia.
Although women are most likely to stop breastfeeding while taking lithium, breastfeeding, some may choose to take lithium while continuing to breastfeed breast.
In such cases, lithium should be used at the lowest effective dose and monitor its concentration in the blood serum of the mother and the newborn.
It is necessary to closely monitor, together with the pediatrician, the condition of the child in order to recognize signs of toxic effects in time lithium, as well as monitor the concentration of lithium, the level of thyroid-stimulating hormone (TSH), creatinine and urea nitrogen (BUN) in his blood every 6-8 weeks during the period the baby is breastfed.
Several recent studies suggest that that the dose of lamotrigine given to newborns through breast milk varies.
At the same time, its concentration in the blood serum of a newborn may be from 20% to 50% of its concentration in the mother's blood serum.
In addition, maternal serum concentrations of lamotrigine increases significantly after childbirth, which is probably the reason for its high serum concentration in infants.
None of these studies indicated any adverse effects in breastfed neonates.
Learn more about the safety of lamotrigine versus lithium here (in English).
Another concern for practitioners and mothers is Stevens-Johnson syndrome .
This is an acute, life-threatening illness most commonly as a result of an allergic reaction to a drug that develops approximately in 0.1% of patients with bipolar disorder taking lamotrigine.
No case reported so far Stevens-Johnson in neonates associated with exposure to lamotrigine.
Apparently, cases of Stevens-Johnson syndrome in newborns caused by a reaction to medications are extremely rare.
Although currently available studies different concentrations of this drug in the blood serum were indicated neonates, none of these studies reported any adverse effects in infants.
Evaluation of the safety of lamotrigine in infants requires further research.
The decision to use this drug in lactating women should be based on a careful analysis of the ratio of risk factors and benefits of its use.
Although the American Academy of Pediatrics considered carbamazepine (tegretol) and valproic acid (depakote) applicable for the treatment of lactating mothers, several studies show the effect of these drugs on health of newborns.
Both of these mood stabilizers are associated with disorders liver function and lethal toxic effects on the liver in adults.
Several cases of liver dysfunction due to exposure to carbamazepine through breast milk.
Of particular concern is the fact that the risk of toxic Liver exposure is highest in children younger than two years of age.
The risk of serious adverse effects is therefore particularly high for children who are breastfed.
If the woman decides to take carbamazepine or valproic acid while continuing to breastfeed is recommended routinely monitor the concentration of the drug in the blood serum of the newborn and carry out liver tests.
In this case, it is essential to act in cooperation with observing the child by a pediatrician.
💢 Antipsychotics
breastfeeding antipsychotics, and data on atypical antipsychotics new generation means are absent.
While the use of chlorpromazine is associated with adverse effects, including lethargy and developmental delay, throughout visibility when using medium- and high-potency preparations unfavorable effects are rare.
However, fewer atypical antipsychotics are available. data.
Clozapine data suggest that it is may accumulate in breast milk.
However, no concentration data are available for this drug in the blood serum of newborns, so it is difficult to assess the significance of this discoveries.
Including serious adverse effects associated with exposure to clozapine in adults (i.e., a decrease in the level of leukocytes in the blood), this drug should be used only in cases of diseases that are difficult to treat treatment.
In this case, it is imperative to monitor the level of leukocytes in blood of a breastfed newborn.
Very limited data available on use in lactation of other atypical antipsychotics.
However, the limited data available for olanzapine risperidone and quetiapine suggest that these drugs penetrate into breast milk in low concentrations and adverse effects on appears to be rare.
It is recommended to monitor the condition of the newborn, as in one report reported a case in which a newborn had when the mother took a higher dose of olanzipamine, lethargy was observed, which passed after the dosage of the drug for the mother was halved to 5 mg/day.
There are currently no studies on breastfeeding use of neuroleptics such as ziprasidone (Geodon) and aripiprazole (Abilify).
💢 Clinical guidelines
drugs for breastfeeding women should discuss the known benefits breastfeeding for maternal and child health, as well as the opportunity penetration of drugs into breast milk.
Although earlier clinical guidelines it was recommended to routinely monitor the concentration of the drug in serum of the newborn, this procedure is most likely not justified.
In most cases in the blood serum of newborns low or undetectable concentrations of drugs are detected, and about adverse effects reported rarely.
However, similar tests are indicated if toxic effects of the drug on the newborn.
It is also necessary to monitor the concentration of the drug in serum blood of a newborn, if the mother takes lithium during breastfeeding, valproic acid, carbamazepine or clozapine.
Scope of scientific evidence for specific drugs varies.
SSRIs have been the best studied for breastfeeding safety.
More specifically, available data show safety these drugs in the short term, while systematized data regarding their safety in the long term perspective are missing.
In this regard, in each individual case, it is necessary to look for balance between known and unknown risks of drug exposure to the child, the risk of untreated disease in the mother and her desire to feed the child breast.
For more up-to-date information on the use of psychiatric drugs while breastfeeding, see womenmentalhealth.org/blog .
Treatment of nursing mothers with sertraline and serotonin transport in mother-infant pairs
Original: ncbi.nlm.nih.gov/pubmed/11578995
Epperson N1, Czarkowski KA, Ward-O'Brien D, Weiss E, Gueorguieva R, Jatlow P, Anderson GM. Am J Psychiatry. 2001 Oct;158(10):1631-7.
Summary
Pharmacological treatment of postpartum depression is often complicated by the mother's desire to continue breastfeeding.
Although the concentration of several selective serotonin reuptake inhibitors (SSRIs) in breast milk are relatively low, the question remains whether exposure to SSRIs leads through breast milk to clinically significant inhibition of serotonin reuptake (5-HT) in newborns.
This study determines the degree of blockade serotonin transporter proteins in neonates exposed to sertraline through mother's breast milk.
METHOD:
To determine the degree of blockade of serotonin transporter proteins in mother and newborn, the content of 5-HT in platelets was measured in fourteen pairs of nursing mothers and their newborns before and after 6-16 weeks treatment with sertraline of maternal depression that began after childbirth.
The concentration of sertraline and desmethyl-sertraline in plasma in 13 of these mothers and 11 of their newborns.
RESULTS:
mothers, there was a significant (70% -96%) decrease in the content of 5-HT in platelets.
While in neonates after exposure to sertraline through breast milk, the content of 5-HT in platelets changed slightly or not changed at all.
Average content of sertraline and its main metabolite desmethyl-sertraline in maternal plasma was 30.7 ng/ml and 45.3 ng/ml, respectively.
Plasma levels of sertraline and its metabolite in neonates was at the lower limit of quantitation or even lower.
